# US 2009/0022761 A1 · Enhancement of Immune Response to Vaccine by Interferon Alpha

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0022761 A1
- Document ID: US20090022761A1
- Status: Published application
- Kind: A1
- Application number: 11/928,704
- Filed: 2007-10-30
- Published: 2009-01-22
- Earliest claimed: 2000-11-09
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: Federico A. Zuckermann
- Web page: https://patentgrep.com/patent/US20090022761A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/12: Viral antigens
- A61K 2039/525: {Virus}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55583: {Polysaccharides}
- C12N 2770/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Exogenous cDNA capable of expressing interferon″ activity, exogenous interferon″ protein, inducers of endogenous interferon″ protein activity, inducers of endogenous interferon $ protein activity, inducers of endogenous interferon′ activity, or inducers of other immune-enhancing activity can be combined with a vaccine to enhance an immune response. Specifically disclosed are adjuvant and vaccine combinations where the adjuvant comprises a cDNA capable of expressing interferon″ activity, a complex comprising polyriboinosinic-polyribocytidilic acid, or a complex comprising polyriboinosinic-polyribocytidilic acid, poly-L-lysine, and carboxymethylcellulose and where the vaccine is a live vaccine virus derived from a virus causing porcine reproductive and respiratory syndrome disease.

## Claims

### Claim 1

An adjuvant composition comprising a nucleic acid capable of expressing an interferon alpha in a pig in an amount sufficient to enhance an immune response to a PRRS virus when administered to the pig.

### Claim 2 (depends on 1)

The adjuvant composition of claim 1 wherein the nucleic acid comprises the sequence of SEQ ID NO:3.

### Claim 3

A method for enhancing an immune response of an animal to a vaccine comprising the steps of:
a. administering a PRRS vaccine antigen composition to an animal in an amount effective to stimulate an immune response; and
b. administering to the animal an adjuvant composition comprising a nucleic acid capable of expressing interferon alpha in an amount effective to potentiate the immune response to the vaccine antigen composition.

### Claim 4 (depends on 3)

The method of claim 3 wherein the interferon alpha is a porcine interferon α.

### Claim 5 (depends on 3)

The method of claim 3 wherein said animal is a non-human mammal.

### Claim 6 (depends on 3)

The method of claim 3 wherein said animal is a pig.

### Claim 7 (depends on 3)

The method of claim 3 wherein said vaccine antigen composition comprises a vaccine antigen selected from the group consisting of live vaccine virus, inactivated vaccine virus, subunit vaccine, and polypeptide vaccine.

### Claim 8 (depends on 7)

The method of claim 7 wherein said live vaccine virus is derived from an agent capable of causing clinical signs of porcine reproductive and respiratory syndrome disease.

### Claim 9 (depends on 7)

The method of claim 7 wherein said live vaccine virus is derived from ATCC-VR2495.

### Claim 11 (depends on 3)

The method of claim 3 wherein said nucleic acid comprises SEQ ID NO:3.

### Claim 12 (depends on 3)

The method of claim 3 wherein said administering steps are independently by a type of administration selected from the group consisting of: parenteral injection, intravenous injection, intranasal inoculation, per os inoculation, intraocular inoculation, inhalation inoculation, transmucosal inoculation, and transdermal inoculation.

### Claim 13 (depends on 12)

The method of claim 12 wherein said administration steps occur by the same or different types of administration.

### Claim 14 (depends on 12)

The method of claim 12 wherein said administration steps are concurrent or sequential.

### Claim 15 (depends on 12)

The method of claim 12 wherein said administration of said adjuvant occurs from one week before to one week after said administration of said vaccine.

### Claim 16 (depends on 12)

The method of claim 12 wherein said vaccine antigen composition comprises a live vaccine virus, further comprising at least one subsequent administration of the live vaccine virus.

### Claim 17 (depends on 12)

The method of claim 12 further comprising at least one subsequent administration of said nucleic acid.

### Claim 18

A composition comprising an effective amount of a PRRS vaccine antigen composition and an effective amount of an adjuvant wherein the adjuvant is a nucleic acid capable of expressing interferon α, wherein the amount of the adjuvant is sufficient to enhance the animal's immune response to the vaccine and wherein the vaccine antigen is present in an amount sufficient to raise an immune response to the antigen.

### Claim 19 (depends on 18)

The composition of claim 18 wherein said vaccine antigen composition comprises a vaccine antigen selected from the group consisting of live vaccine virus, inactivated vaccine virus, subunit vaccine, and polypeptide vaccine.

### Claim 20 (depends on 19)

The composition of claim 19 wherein said live vaccine virus is derived from an agent capable of causing clinical signs of porcine reproductive and respiratory syndrome disease.

### Claim 21 (depends on 19)

The composition of claim 19 wherein said live vaccine virus is derived from ATCC-VR2495.

### Claim 22 (depends on 18)

The composition of claim 18 wherein said nucleic acid is capable of expressing porcine interferon α.
